ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

Treatment with imatinib results in good overall survival in patients with chronic myeloid leukemia, approaching a normal life expectancy, according to the CML-IV study.

The FDA has granted priority review status for two new indications of dasatinib (Sprycel), according to the drug’s developer.

Approximately half of patients with chronic-phase CML who achieved a sustained deep molecular response with nilotinib were able to discontinue therapy and remain in treatment-free remission through 96 weeks.

A de-escalation of tyrosine-kinase inhibitor dose was safe in the majority of patients with chronic myeloid leukemia with stable major molecular response.

Dasatinib was safe and effective in pediatric patients with chronic myeloid leukemia, according to a new study, establishing the agent as a new standard of care for this population.

This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients.

Ahead of the 2017 ASCO Annual Meeting, we discuss the discontinuation of TKIs in some chronic myeloid leukemia patients.

Pages

Subscribe to Chronic Myeloid Leukemia on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.